The histone deacetylase inhibitor sodium butyrate protects against cisplatin-induced hearing loss in guinea pigs Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Butyrates
  • Cisplatin
  • Hearing Loss, Sensorineural
  • Neuroprotective Agents

abstract

  • The histone deacetylase inhibitor sodium butyrate gives almost complete protection in a single-dose model of cisplatin ototoxicity in guinea pigs. Because histone deacetylase inhibitors are anticancer agents with very few side effects, they may be candidates for clinical use during cisplatin chemotherapy.

publication date

  • February 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2570099

Digital Object Identifier (DOI)

  • 10.1097/01.mlg.0000197630.85208.36

PubMed ID

  • 16467722

Additional Document Info

start page

  • 292

end page

  • 6

volume

  • 116

number

  • 2